Down 13.5% today, more than its biotech peers' 2.4%; no story names it yet.
Fell 15% since Oct 28
Down 15% from Oct 28 to Oct 30 while the S&P 500 fell 2%.
Follow PROK's trial news. Pro members can get an alert when ProKidney files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 42.7% more shares than a year ago |
| Latest filing | 8-K, Oct 29 |
TodayNo story names it yet.
Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.
After its last 4 reports it closed -2.6% on average, higher 1 of 4 times.
About 2 quarters
No shelf registration or at-the-market program on file in the last three years.
Director Brian Jg Pereira sold 757,164 shares on Aug 20.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
PROK is #240 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 240 |
Expected to report Mon Nov 9, after the close (in 7 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase of $10.2 million was driven by increases in clinical study and related manufacturing costs of $8.7 million, primarily related to our ongoing PROACT 1 study.”
PROK's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease of $1.6 million was driven primarily by decreases in compensation costs of approximately $1.2 million due to vesting of awards issued prior to our business combination in 2022, coupled with forfeitures of equity-based awards and reductions in severance costs.”
From its results filing (SEC filing · Aug 10)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 10, 2026 | -4.7% | -4.7% | -17.2% |
| May 15, 2026 | 0.0% | -3.0% | +5.4% |
| Mar 18, 2026 | -1.0% | -6.3% | -12.0% |
Sales grew in two of the last three years, to $893K in 2025. It lost money in each of the three years.
One insider sold $1.1M across 6 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
“The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition, and an emphasis on intellectual property.”
PROK scores -6 today, which Breakaway calls Poor. It is #240 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 15% from Oct 28 to Oct 30 while the S&P 500 fell 2%. Cash lasts about 2 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PROK scores -6 today, which Breakaway calls Poor (below zero). That is #240 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PROK's -6.
One insider sold $1.1M across 6 filings in the last 6 months. No open-market buys on record. The newest is Brian Jg Pereira, Director, who sold $321K on Aug 19. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.